Literature DB >> 20417751

When should prophylactic maze procedure be considered in patients undergoing mitral valve surgery?

John M Stulak1, Rakesh M Suri, Joseph A Dearani, Thoralf M Sundt, Hartzell V Schaff.   

Abstract

BACKGROUND: Some patients are at high risk for late atrial fibrillation (AF) after mitral valve surgery, even without a prior history of arrhythmias. We examined the incidence and predictors of late AF in patients with functional tricuspid regurgitation (TR) undergoing mitral valve repair.
METHODS: From March 1995 to December 2005, 573 patients (375 men) with severe mitral regurgitation owing to leaflet prolapse and functional TR underwent mitral valve repair; 75 patients (13%) had greater than mild TR preoperatively. We excluded patients with preoperative AF or other cardiac disease. We assessed late rhythm status, and results were expressed as a time-related event. A separate cohort of patients undergoing tricuspid valve repair was compared.
RESULTS: Cumulative risk of late AF was 11% at 5 years and 23% at 10 years (>mild preoperative TR, 23% versus <mild TR, 9%; p = 0.0007). In a multivariable model, the risk of late AF was independently associated with advanced age (hazard ratio [HR], 1.05), left atrial size greater than 50 mm (HR, 1.06), greater than mild preoperative TR (HR, 2.3), and diabetes (HR, 4.8). Patients undergoing tricuspid valve repair (n = 25) had a similar risk of late AF at 5 years (tricuspid valve surgery, 18% versus no tricuspid valve surgery, 23%; p = 0.439). When analyzed as a time-dependent risk factor, patients with late AF had decreased late survival (HR, 4.01; p = 0.001).
CONCLUSIONS: New, late-onset AF after mitral valve repair for leaflet prolapse is significantly increased in patients with greater degrees of preoperative TR, and late survival is subsequently decreased. To avoid the adverse consequences of late AF, the addition of surgical AF ablation may be warranted. Copyright (c) 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20417751     DOI: 10.1016/j.athoracsur.2010.02.018

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

Review 1.  Evidence-based surgical management of acquired tricuspid valve disease.

Authors:  Sung Ho Shinn; Hartzell V Schaff
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

2.  Incidence and predictors of de novo late-onset persistent atrial fibrillation in postoperative rheumatic heart disease patients (LOAF-RHD study).

Authors:  Gautam Sharma; Nirmal Ghati; Shrenik Doshi; Shruti Sharma; Mohd Sharique; Aman Agarwal; Velayoudam Devagourou; Milind Padmakar Hote; Shiv Kumar Choudhary
Journal:  J Interv Card Electrophysiol       Date:  2021-11-08       Impact factor: 1.759

3.  Evolving indications for tricuspid valve surgery.

Authors:  Patrick M McCarthy; Virna L Sales
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-12

Review 4.  RNAs and Gene Expression Predicting Postoperative Atrial Fibrillation in Cardiac Surgery Patients Undergoing Coronary Artery Bypass Grafting.

Authors:  Muhammad Shuja Khan; Kennosuke Yamashita; Vikas Sharma; Ravi Ranjan; Derek James Dosdall
Journal:  J Clin Med       Date:  2020-04-16       Impact factor: 4.241

Review 5.  Advances in catheter ablation: atrial fibrillation ablation in patients with mitral mechanical prosthetic valve.

Authors:  Pasquale Santangeli; Luigi Di Biase; Rong Bai; Rodney Horton; J David Burkhardt; Javier Sanchez; Justin Price; Andrea Natale
Journal:  Curr Cardiol Rev       Date:  2012-11

Review 6.  Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors.

Authors:  Erez Marcusohn; Ofer Kobo; Maria Postnikov; Danny Epstein; Yoram Agmon; Lior Gepstein; Yaron Hellman; Robert Zukermann
Journal:  Card Fail Rev       Date:  2021-11-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.